FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564164047> ?p ?o ?g. }

• W2564164047 endingPage "kew442" @default.
• W2564164047 startingPage "kew442" @default.
• W2564164047 abstract "To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA.Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i.e. no b/ts-DMARD treatment), based on subjects experiencing an event in relation to person-years. Confidence in the estimates was assessed by applying the Grading of Recommendations Assessment, Development and Evaluation approach (GRADE).A total of 117 trials (47 615 patients) were included. SAEs were more common with certolizumab compared with abatacept (rate ratio = 1.58, 95% CI: 1.18, 2.14), adalimumab (1.36, 95% CI: 1.02, 1.81), etanercept (1.60, 95% CI: 1.18, 2.17), golimumab (1.45, 95% CI: 1.00, 2.08), rituximab (1.63, 95% CI: 1.16, 2.30), tofacitinib (1.44, 95% CI: 1.03, 2.02) and control (1.45, 95% CI: 1.13, 1.87); and tocilizumab compared with abatacept (1.30, 95% CI: 1.03, 1.65), etanercept (1.31, 95% CI: 1.04, 1.67) and rituximab (1.34, 95% CI: 1.01, 1.78). No other comparisons were statistically significant. Accounting for study duration confirmed our findings for up to 6 months' treatment but not for longer-term treatment (6-24 months). No differences in mortality between b/ts-DMARDs and control were found. Based on the GRADE approach, confidence in the estimates was low due to lack of head-to-head comparison trials and imprecision in indirect estimates.Despite low confidence in the estimates, our analysis found potential differences in rates of SAEs. Our data suggest caution should be taken when deciding among available drugs.PROSPERO CRD42014014842." @default.
• W2564164047 created "2017-01-06" @default.
• W2564164047 creator A5009515583 @default.
• W2564164047 creator A5015244702 @default.
• W2564164047 creator A5019980330 @default.
• W2564164047 creator A5023604084 @default.
• W2564164047 creator A5029214522 @default.
• W2564164047 creator A5043915305 @default.
• W2564164047 creator A5044831604 @default.
• W2564164047 creator A5057994974 @default.
• W2564164047 creator A5059206584 @default.
• W2564164047 creator A5064779058 @default.
• W2564164047 creator A5066663009 @default.
• W2564164047 creator A5073795723 @default.
• W2564164047 date "2016-12-24" @default.
• W2564164047 modified "2023-10-03" @default.
• W2564164047 title "Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis" @default.
• W2564164047 cites W1596092785 @default.
• W2564164047 cites W1701993624 @default.
• W2564164047 cites W1872421448 @default.
• W2564164047 cites W1973460930 @default.
• W2564164047 cites W1986360186 @default.
• W2564164047 cites W1989467621 @default.
• W2564164047 cites W2006566716 @default.
• W2564164047 cites W2009093622 @default.
• W2564164047 cites W2012932483 @default.
• W2564164047 cites W2013144056 @default.
• W2564164047 cites W2015215846 @default.
• W2564164047 cites W2017076873 @default.
• W2564164047 cites W2019832147 @default.
• W2564164047 cites W2060549798 @default.
• W2564164047 cites W2077653789 @default.
• W2564164047 cites W2080902390 @default.
• W2564164047 cites W2085318733 @default.
• W2564164047 cites W2093884168 @default.
• W2564164047 cites W2098923148 @default.
• W2564164047 cites W2115193081 @default.
• W2564164047 cites W2126629865 @default.
• W2564164047 cites W2128076015 @default.
• W2564164047 cites W2131254861 @default.
• W2564164047 cites W2131882149 @default.
• W2564164047 cites W2136403658 @default.
• W2564164047 cites W2137053633 @default.
• W2564164047 cites W2142004396 @default.
• W2564164047 cites W2147648627 @default.
• W2564164047 cites W2147700719 @default.
• W2564164047 cites W2152348310 @default.
• W2564164047 cites W2154986972 @default.
• W2564164047 cites W2155798268 @default.
• W2564164047 cites W2164586769 @default.
• W2564164047 cites W4210768724 @default.
• W2564164047 doi "https://doi.org/10.1093/rheumatology/kew442" @default.
• W2564164047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28013201" @default.
• W2564164047 hasPublicationYear "2016" @default.
• W2564164047 type Work @default.
• W2564164047 sameAs 2564164047 @default.
• W2564164047 citedByCount "31" @default.
• W2564164047 countsByYear W25641640472017 @default.
• W2564164047 countsByYear W25641640472018 @default.
• W2564164047 countsByYear W25641640472019 @default.
• W2564164047 countsByYear W25641640472020 @default.
• W2564164047 countsByYear W25641640472021 @default.
• W2564164047 countsByYear W25641640472022 @default.
• W2564164047 crossrefType "journal-article" @default.
• W2564164047 hasAuthorship W2564164047A5009515583 @default.
• W2564164047 hasAuthorship W2564164047A5015244702 @default.
• W2564164047 hasAuthorship W2564164047A5019980330 @default.
• W2564164047 hasAuthorship W2564164047A5023604084 @default.
• W2564164047 hasAuthorship W2564164047A5029214522 @default.
• W2564164047 hasAuthorship W2564164047A5043915305 @default.
• W2564164047 hasAuthorship W2564164047A5044831604 @default.
• W2564164047 hasAuthorship W2564164047A5057994974 @default.
• W2564164047 hasAuthorship W2564164047A5059206584 @default.
• W2564164047 hasAuthorship W2564164047A5064779058 @default.
• W2564164047 hasAuthorship W2564164047A5066663009 @default.
• W2564164047 hasAuthorship W2564164047A5073795723 @default.
• W2564164047 hasBestOaLocation W25641640471 @default.
• W2564164047 hasConcept C126322002 @default.
• W2564164047 hasConcept C168563851 @default.
• W2564164047 hasConcept C197934379 @default.
• W2564164047 hasConcept C2777178219 @default.
• W2564164047 hasConcept C2777226972 @default.
• W2564164047 hasConcept C2777575956 @default.
• W2564164047 hasConcept C2778886723 @default.
• W2564164047 hasConcept C2779338263 @default.
• W2564164047 hasConcept C2779605438 @default.
• W2564164047 hasConcept C2780132546 @default.
• W2564164047 hasConcept C2780653079 @default.
• W2564164047 hasConcept C2781290027 @default.
• W2564164047 hasConcept C44249647 @default.
• W2564164047 hasConcept C71924100 @default.
• W2564164047 hasConcept C95190672 @default.
• W2564164047 hasConceptScore W2564164047C126322002 @default.
• W2564164047 hasConceptScore W2564164047C168563851 @default.
• W2564164047 hasConceptScore W2564164047C197934379 @default.
• W2564164047 hasConceptScore W2564164047C2777178219 @default.
• W2564164047 hasConceptScore W2564164047C2777226972 @default.
• W2564164047 hasConceptScore W2564164047C2777575956 @default.

• next